For injections that are fast, safe, and virtually pain free - Needle-free INJEX syringes now sold in Canada

QUEBEC CITY, March 26, 2013 /CNW Telbec/ - Millions of Canadians will be glad to hear that needle-free INJEX syringes are now available for purchase from Marketing Medical Canada Inc., a Quebec-based Canadian company specializing in the international distribution of innovative health products. INJEX syringes draw on the principles of biomechanics to deliver virtually pain-free injections directly into subcutaneous fatty tissue. INJEX improves patient quality of life by greatly reducing the discomfort and fear that may come with conventional needle injections.

Approved by Health Canada in August 2012, the needle-free injector is revolutionizing the way injections are administered. Clinical studies have shown that INJEX preserves the integrity of body tissue, causing no damage to blood vessels, nerve fibers, or bone tissue. INJEX syringes distribute medication better and are safer to handle than conventional needles.

A product that will improve quality of life for millions of Canadians
Because it is so easy and safe to use, INJEX can improve the quality of life for people with a variety of needs:

  • Insulin injections for treating diabetes
  • Local anesthesia in dentistry
  • Vaccinations for children and adults, as well as hormone injections (e.g., infertility treatment)
  • Aesthetic medicine uses, such as anti-aging, skin-correcting, and other cosmetic treatments

"INJEX is a proven German invention that is already available in many countries. Numerous clinical tests have demonstrated its safety and efficacy. This injector can be used to administer a variety of medications and is designed to be equally easy whether users are self-medicating or health professionals. We are very proud to offer this innovative technology to millions of diabetics and people who fear needles," said Benoit Côte, Chairman of Marketing Medical Canada Inc. (MMC).

MMC holds the exclusive distribution rights for INJEX in Canada, France, Mexico, and Algeria. MMC began selling INJEX in Mexico in early 2013, working with a leading local partner. Mr. Côte, MMC chairman, has been active in business and corporate development for 25 years, particularly in the health sector. He has held senior management positions and served on boards of directors of major private and public corporations and government agencies in Canada.

INJEX: the solution to multiple challenges
INJEX presents multiple advantages: it lowers blood absorption time for various medications or active ingredients administered subcutaneously, reduces the risk of occupational healthcare-related injuries (needlestick accidents, infection transmission), and slashes biomedical waste disposal costs.

INJEX fits with the burgeoning trend of self-administered medications. For example, it allows patients with reduced mobility to self-administer their medication safely without leaving home. This product also meets a growing demand for pain-free drug delivery devices. The global needle-free syringe market was valued at US$755 million in 2008 and is expected to grow 54% between 2008 and 2015. (Source: www.worldpharmaceuticals.net/editorials/018/WPF018_afuture-free.pdf)

How INJEX works
The INJEX injector propels fluid through a micro-orifice in the skin cells using a precise amount of spring-powered pressure. An extremely fine jet (0.17 mm) of fluid gently enters the subcutaneous fatty tissue where there is the least resistance. Penetration depth varies between 3.2 to 9.1 mm, depending on the volume of fluid administered. With INJEX, fluid disperses evenly over a wider surface instead of forming a pocket, as with conventional needle injections. Its compact size (96 mm) and light weight (75 g) make INJEX the ideal self-injection device.

How to get INJEX
The INJEX device is composed of a reusable injector, resetbox, transporter, and sterile ampoules and adapters. Made of stainless steel and backed by a five-year warranty, INJEX is designed to deliver approximately 5,000 injections. To purchase the product, contact MMC by phone at 1-855-823-5533 or email info@injex.ca. INJEX will be available soon from medical equipment distributors and selected specialist retailers.

IMAGE CAPTURE: INJEX demonstrations with patients available

SPOKESPERSON: Benoit Côte, MMC Chairman

To watch an instructive video: http://injex.ca/en/products/video-product

To download photos: http://injex.ca/en/medias/

To consult INJEX clinical studies: www.injex.com/studiengesamt

SOURCE: INJEX

For further information:

Source:   Marketing Medical Canada Inc.

For information: Sarah Moreau
Senior consultant
Hill+Knowlton Strategies
Telephone: 514 395-0375 ext.: 234
Cell: 514 219-2764
Email: sarah.moreau@hkstrategies.ca